Effects of rosiglitazone on cardiovascular parameters in postmenopausal nondiabetic women with or without hormone therapy

Trial Profile

Effects of rosiglitazone on cardiovascular parameters in postmenopausal nondiabetic women with or without hormone therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2013

At a glance

  • Drugs Rosiglitazone (Primary) ; Conjugated estrogens; Progesterone congeners
  • Indications Cardiovascular disorders; Insulin resistance; Menopausal syndrome
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 16 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top